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Abstract 
Purpose of review: Urine is the most useful of body fluids for biomarker research. Therefore, 
we have focused on urinary proteomics, using capillary electrophoresis coupled to mass 
spectrometry (CE-MS), to investigate kidney disease in recent years.  
Recent Findings: Several urinary proteomics studies for the detection of various kidney 
diseases have indicated the potential of this approach aimed at diagnostic and prognostic 
assessment. Urinary protein biomarkers such as collagen fragments, serum albumin, alpha-1-
antitrypsin, and uromodulin can help to explain the processes involved during disease 
progression.  
Summary: Urinary proteomics has been used in several studies, in order to identify and 
validate biomarkers associated with different kidney diseases. These biomarkers, with 
improved sensitivity and specificity when compared to the current gold standards, provide a 
significant alternative for diagnosis and prognosis, as well as improving clinic decision 
making. 
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Introduction 
Renal function is essential for maintaining body homeostasis by contributing to the control of 
blood composition, pressure, volume and pH (1). Proteomics, the analysis of the total protein 
content of a sample, is a field of research constantly evolving and during the last decade 
several techniques have been developed to analyze and characterize the proteome of samples 
from very different origins (2). Urinary proteomics has become an essential tool for the 
discovery of novel biomarkers in kidney disease. It has been shown to contribute to early 
diagnosis and clinical assessment, based on better insight into kidney disease and its 
development (3)*. 
 
Current situation of clinical proteomics 
In the last two decades, mass spectrometry (MS) has become one of the most prevalent 
techniques in the detection and characterization of proteins and peptides (4). Techniques such 
as two-dimensional gel electrophoresis (2-DE), liquid chromatography (LC), surface 
enhanced laser desorption/ionization (SELDI), and capillary electrophoresis (CE) coupled 
with MS have had a significant impact in biology and medicine. The advantages and 
disadvantages of these different proteomics approaches have been described in a number of 
reviews in detail (5-7). Although a large number of studies have been published on the use of 
proteomics for the identification of biomarkers for diseases, they often had significant 
shortcomings, e.g. absence of appropriate statistical assessment, insufficient power, or lack of 
validation in an independent cohort. Sparked by these observations, recommendations for 
biomarker research in the field of clinical proteomics were elaborated to improve the validity 
of biomarkers identified in these studies (8-10).  
 
Recent urinary proteomic biomarker studies 
Several clinical urinary proteomic studies in kidney diseases conforming to the above 
recommendations were recently (last five years) published. However, most of them are based 
on capillary electrophoresis coupled to mass spectrometry (CE-MS). In the next sections, 
these studies will be discussed in detail and are listed in Table 1, as well as depicted in 
Figure 1. 
 
Chronic Kidney Diseases 
Chronic kidney disease (CKD) is defined as the progressive loss of kidney function and a 
reduction in the glomerular filtration rate (GFR) which can result in end-stage renal disease 
(ESRD). At this stage, the patients require renal replacement therapies like dialysis or kidney 
transplantation (11). The most common causes of CKD are diabetic nephropathy (DN), 
hypertension, and glomerulonephritis (12). DN is caused by diabetes mellitus, a chronic 
metabolic disease, associated with cardiovascular and renal complications. CKD diagnosis is 
currently obtained by the detection of alterations in estimated glomerular filtration rate 
(eGFR) and/or albuminuria as indicators of renal dysfunction (11). However, eGFR has 
limited value in predicting risk of CKD progression unless substantially reduced. Instead (or 
together with eGFR) albuminuria is often used even though, in a non-negligible number of 
patients, renal disease progresses despite the absence of albuminuria (13). 
Over the last five years CE-MS has been a frequently used proteomics approach to discover 
urinary biomarkers for the diagnosis and prognosis of CKD (see Figure 2). The basis for all 
these validation studies was a publication in 2010 (14). Using CE-MS, Good et al. were able 
to define 273 urinary peptide markers for CKD (named the “CKD273-classifier”) in a cohort 
of 379 healthy controls and 230 patients with CKD derived from different etiologies. These 
peptide markers were mostly different fragments of various collagens, blood proteins (e.g. 
serum albumin, α-1-antitrypsin) and specific kidney-derived proteins (e.g. uromodulin). In 
order to validate the defined biomarkers, Good et al. applied the CKD273-classifier to a set of 
144 samples consisting of 34 controls and 110 patients with CKD, showing a sensitivity of 
85% and specificity of 100% (AUC=0.96).  
This CKD273-classifier was further validated in several independent studies with patients 
with CKD derived from different origins: The first study was to validate the diagnostic 
performance in patients suffering from type 2 diabetes. Molin et al. compared 137 urine 
samples (62 patients and 75 controls), based on CKD273-classifier (15). The validation 
resulted in a similar accuracy (AUC=0.96) as in the initial discovery study (14). Argilés et al. 
examined the CKD273-classifier based on a cohort of 53 patients with CKD at different 
stages, where the CKD273-classifier enabled prediction of ESRD or death (16). Gu et al. also 
confirmed the ability of the CDK273-classifier to predict progression of CKD in a cohort of 
797 individuals. With an average follow-up time of 4.8 years, this validation effectively 
predicted development of renal dysfunction and cardiovascular complications (17). Zürbig et 
al. studied the prognosis of DN with the use of the CKD273-classifier in a longitudinal study 
of normoalbuminuric diabetic individuals (18). The authors were able to predict progression 
to macroalbuminuria over 5 years with an AUC of 0.93 superior to baseline albuminuria 
(AUC=0.67). Furthermore, the CKD273-classifier identified the progressors in 65% of the 
case subjects earlier than urinary albumin, the standard clinical test. On average the CKD273-
classifier detected progression 1.5 years earlier than microalbuminuria. In a similar study with 
a follow-up over 3 years, Roscioni et al. evaluated the prediction of the transition from 
normo- to microalbuminuria and from micro- to macroalbuminuria (19). In a cohort of 44 
patients with type 2 diabetes, the CKD273-classifier allowed assessment of early renal risk in 
diabetic patients. Recently, the CKD273-classifier was also validated in a cohort of 18 
patients with CKD stage 4-5 (of whom six had hypertensive nephropathy) and 17 healthy 
controls, in order to compare the prevalence of CKD and progression beyond albuminuria 
(20)*. Special intention was paid to the diagnosis of hypertensive nephropathy, because it is 
surprisingly understudied, and proteomic analyses has never been performed (21). The results 
showed that the classifier performed equally well in patients with hypertensive nephropathy 
as in patients with other CKD causes. 
A further validation of the classifier was obtained in assessing treatment. Using the CKD273-
classifier, Andersen et al. analysed the effects of Irbesartan, an angiotensin receptor blocker, 
in a cohort of patients with type 2 diabetes with microalbuminuria (22). The scores of the 
classifier changed significantly after treatment with Irbesartan to values of more healthy 
individuals. Furthermore, the authors identified several peptides that showed significant 
change after 2 years with Irbesartan treatment in contrast to placebo. After Irbesartan 
treatment, an increase of collagen fragments showed the most significant association with 
DN. These results have led to the initiation of the PRIORITY study (23)* in order to evaluate 
the value of urinary proteomics in patient stratification for the presence of early signs of DN 
in an interventional trial. In this context, 165 type 2 diabetes patients were analysed with the 
CKD273-classifier assessing the benefits of stratifying patients for intervention with urinary 
proteomics (24).  
Recent validation studies used much larger cohorts of individuals with different stages of 
CKD for the assessment of the prognostic potential of the CKD273-classifier: In a large cross-
sectional multicenter cohort of 1990 individuals, including 522 with follow-up data, Schanstra 
et al. correlated the CKD273-classifier score with the estimated glomerular filtration rate 
(eGFR) and its decline (25)**. They validated that the CKD273-classifier performed 
significantly better in detecting and predicting progression of CKD than the current clinical 
standard, urinary albumin. The classifier was also more sensitive for identifying patients with 
rapidly progressing CKD. Compared with the combination of baseline eGFR and albuminuria 
(AUC=0.76), the addition of the CKD273-classifier significantly improved CKD risk 
prediction (AUC=0.83). In addition, when applying the Oxford Evidence-Based Medicine 
(EBM) and Strength of Recommendation Taxonomy (SORT) guidelines, additional evidence 
was obtained which supports the CKD273-classifier’s value in predicting CKD progression 
(26). In a recent study, the classifier and urinary albumin excretion was compared to predict 
the progression of CKD, involving 2672 patients at different CKD stages. The findings 
confirmed that the CKD273-classifier has a better performance at early stages of disease. On 
the other hand urinary albumin was a better predictor for progression at a late stage. In 
moderately advanced disease, these two tests had similar predictive abilities (27)**.  
 
In spite of its invasive nature and risks, kidney biopsy is currently required for precise 
diagnosis of many chronic kidney diseases (CKDs). Therefore, specific biomarkers for 
different types of CKD, such as ANCA-associated vasculitis, IgAN, and DN, were defined 
using urinary proteome analysis. The value of CE-MS-based proteomics to differentiate types 
of CKD etiologies was demonstrated, but mostly in small patient populations (28-31). A 
recent study from Siwy et al. (32)** was designed with the aim of identifying specific urinary 
peptide markers for main types of CKD using datasets from a large cohort of 1180 individuals 
with CKD. For seven different types of CKD (primary focal segmental glomerulosclerosis, 
IgA nephropathy, minimal-change disease, membranous nephropathy, diabetic and 
hypertensive nephropathy, lupus nephritis, and vasculitis-induced kidney disease), several 
potential urinary biomarker peptides (ranging from 116 to 619 peptides, see Table 1) were 
defined and combined into classifiers specific for each CKD. These classifiers were validated 
in an independent cohort and showed good to excellent accuracy for discrimination of one 
CKD etiology from the other (AUCs ranged from 0.77 to 0.95). 
 
Polycystic kidney disease 
The most common genetic disorder in kidney disease (1:400 and 1:1000 individuals) is 
autosomal dominant polycystic kidney disease (ADPKD), a mutation in PKD1 (85% of cases) 
and PKD2 (15% of cases), results in cyst formation and loss of renal function (33;34). Kistler 
et al. (35) performed CE-MS analysis to identify peptide markers for ADPKD. Urine samples 
from 41 ADPKD patients and 189 healthy controls were analyzed leading to the identification 
of 142 consistent peptide biomarkers associated with ADPKD. Combined in a panel, these 
markers classified an independent validation cohort of 251 ADPKD patients from five 
different centres and 86 healthy controls with 84.5% of sensitivity and 94.2% of specificity 
(35). As in the CKD273 classifier, most of the urinary biomarkers were fragments of 
collagen, which may indicate changes in extracellular matrix during cyst formation. In a 
recent study involving 221 ADPKD patients aged 15-46 years and followed-up for 10-13 
years, urinary proteome analysis using CE-MS generated a 20 peptide-based classifier 
allowing prediction of progression risk in ADPKD patients to ESRD (36)**. Prediction of the 
proteases involved in generation of these peptides, was performed suggesting modification of 
matrix metalloproteinases and cathepsin activity in ADPKD patients progressing to ESRD. 
 
Fabry induced kidney disease 
Fabry disease is a rare X-linked lysosomal inherited disorder characterized by deficient 
enzymatic activity of α-galactosidase A (GLA) (37;38), which can cause a wide range of 
systemic symptoms (like pain, kidney involvement, and cardiac manifestations). Fabry 
induced kidney disease (FIKD) is a glomerular disease, which was investigated by Kistler et 
al. (39). Urine samples from 35 treatment-naive female Fabry patients and 89 age-matched 
healthy controls were collected and analysed by CE-MS. A classifier was established based 
on 64 urinary peptides for FIKD diagnosis, with high specificity (97.8%) and sensitivity 
(88.2%) in an independent cohort composed by 17 treatment-naive Fabry patients and 45 
controls. The most common of the sequenced peptides were collagen and uromodulin 
fragments. Interestingly, the up-regulated collagen fragments exhibited one of two 
characteristic C-terminal motivs, PPG or PGP. Furthermore, the uromodulin fragments (all 
were C-terminal fragments) were also up-regulated as in another recent urinary proteomic 
study of Fabry disease (40).  
 Congenital anomalies of the kidney and urinary tract  
Congenital anomalies of the kidney and urinary tract (CAKUT) constitute approximately 20-
30% of all anomalies identified in the prenatal period (41). Defects can be bilateral or 
unilateral, and different defects often coexist. Because CAKUT plays a causative role in 30-
50% of cases of ESRD in children (42), it is important to diagnose these anomalies and 
initiate therapy to minimize renal damage, preventing or delaying the onset of ESRD, and 
providing supportive care to avoid complications of ESRD. CAKUT manifest as structural 
abnormalities of the kidney, including obstructive uropathy, renal dysplasia and urinary tract 
malformations (43). CAKUT displays an extensive spectrum of prenatal and postnatal 
outcomes alternating from death in utero to normal postnatal renal function (44). 
Posterior urethral valves (PUV), the prototypic bilateral CAKUT is an obstructing membrane 
in the posterior male urethra. Klein et al. (45) studied the fetal urinary peptidome with CE-
MS in a cohort of 28 patients with PUV. They identified 26 fetal urinary peptides associated 
with fetuses with PUV displaying early ESRD. Twelve of these peptides were combined in a 
model (12PUV-classifier). This classifier allowed correct prediction of postnatal renal 
function with 88% sensitivity and 95% specificity, in an independent blinded cohort of 38 
PUV patients. Collagen fragments were the main constituents of the classifier, and in contrast 
to the collagen fragments associated with CKD in postnatal urine in adults, the abundance of 
collagen fragments, was increased in fetal urine of patients with PUV displaying severe 
ESRD (44). 
Ureteropelvic junction obstruction (UPJO) is a frequent cause of congenital obstructive 
nephropathy and is characterized by a stenosis between the ureter and the kidney, inducing  
accumulation of urine in renal pelvis and calyces, called hydronephrosis (46;47). In severe 
cases this condition is treated surgically. However, in the milder UPJO cases (often) invasive 
surveillance is necessary during the first years of life to determine whether surgery is 
necessary. Urinary proteome analysis was employed by Decramer et al. in 2006 to determine 
the presence of urinary markers that could predict the progression of UPJO at an early stage 
(48). They identified 51 markers that combined in a classifier predicting progression of UPJO 
with the need of surgical intervention several months in advance. Drube et al. (49) validated 
this classifier in an independent study with 27 pediatric patients. In 19 children <1 year old, 
the model for UPJO showed 83% sensitivity and 92% specificity. On the other hand, in older 
patients, the analysis yielded a sensitivity and specificity of 20% and 66%, respectively. This 
suggests that classifiers should be validated within their context of use, in this case detection 
of severe UPJO before the age of 1 year. Bandin et al. (50) used urinary proteome analysis to 
suggest that early surgery in UPJO might be beneficial compared to classical conservative 
clinical surveillance of the disease. At 5-year follow-up urinary proteomes were similar 
between patients with early surgical correction of UPJO and age matched controls. In 
contrast, urinary proteomes differed significantly between conservatively followed patients 
and controls. Analyses of the proteome differences suggested ongoing renal or ureteral 
remodeling in the conservatively followed patients that was not clinically visible. 
High-grade vesicoureteral reflux (VUR) is described by an abnormal condition of flow of the 
urine from the bladder to the kidney during micturition. This condition is a risk factor for 
impaired renal function, renal scarring and arterial hypertension, although is not a frequent 
condition in children. Current diagnosis requires an invasive and highly uncomfortable 
method - voiding cystourethrography (VCUG). Drube et al. studied a cohort of 73 children 
with the use of CE-MS analysis (51). In this case-control study, a VUR-classifier was 
established in 18 patients with primary VUR grade IV or V, distinguishing these from 19 
patients without VUR. This VUR-classifier was independently validated in a blinded cohort 
of 17 patients with VUR grade IV or V and 19 patients without VUR with a sensitivity of 
88% and a specificity of 79%. Five of the urinary peptides of the classifier were sequenced. 
Three were fragments of collagen alpha-1 (I) chain and the other two were fragments of 
sodium/ potassium-transporting ATPase and of CD99 antigen. 
 
Conclusion 
Urinary proteomics using CE-MS has identified a number of peptide classifiers that can 
become an important alternative for diagnosis and prognosis of kidney disease compared to 
the current, often poorly performing, invasive clinical tests. Several urinary biomarkers were 
identified including fragments from different collagens, serum albumin, alpha-1-antitrypsin 
and uromodulin which could also provide more information regarding the patho-physiology 
of kidney disease and ongoing disease progression. In the near future these different 
biomarker classifiers could be applied in clinical trials as well as in clinical practice, with the 
aim of improving the benefits for the patients with respect to early intervention or 
stratification. 
 
Key points 
 The urinary proteomic classifier, CKD273, was validated in several independent 
studies to be significantly associated with chronic kidney disease (CKD) and to 
enable detection of CKD at very early stages of the disease superior to albuminuria. 
 First multicentre interventional trial with the use of urinary proteomic biomarkers is 
used to target a preventive and therapeutic approach in clinical practice (stratified 
medicine). 
 Differential diagnosis of CKD subtypes with the use of proteome analysis, in contrast 
to biopsy, offers the possibility of being applied early in the course of the disease 
when the benefit of intervention is optimal and of being repeated without any risk for 
the patient. 
 Urinary proteome analysis can also be applied for the diagnosis and prognosis of 
other kidney diseases, like autosomal dominant polycystic kidney disease or 
ureteropelvic junction obstruction. 
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Bulleted references 
* of special interest: 
(3): This Review describes the current status of proteomic and protein biomarkers in the 
context of kidney diseases and also includes an overview of protein-based biomarker 
candidates that are undergoing development for use in nephrology, focusing on those with the 
greatest potential for clinical implementation. It is an excellent guidance for the design of 
future proteomic studies. 
(20): Beside the general validation of the CKD273-classifier, this study also pointed out the 
utilisation of the classifier especially in patients with hypertensive nephropathy for the 
diagnosis and prognosis of CKD. 
(23): This article describes the study design and background of the first prospective 
multicentre clinical trial (PRIORITY) with the aim to confirm performance of CKD273 and 
to test the ability of spironolactone to delay progression of early diabetic nephropathy. 
 
** of outstanding interest: 
(25): The study of a large cross-sectional multicenter cohort of 1990 individuals validated that 
CKD273-classifier performed significantly better in detecting and predicting progression of 
CKD than urinary albumin. The classifier was also more sensitive for identifying patients 
with rapidly progressing CKD. 
(27): This study is a multicentre, large-scale validation of the CKD273-classifier. Here, the 
prognostic ability of the classifier versus albuminuria was tested at different disease stages. 
The results suggest that the CKD273-classifier allow the detection of progressive disease at 
early CKD stages, at which therapeutic intervention is likely more effective. 
(32): In this study urinary proteome analysis clearly differentiated various types of CKD. In 
contrast to kidney biopsy, this offers the possibility of being applied early in the course of the 
disease when the benefit of intervention is optimal and of being repeated without any risk for 
the patient and, thus, can be used to monitor treatment response. 
(36): In this study, a classifier was developed based on urinary proteome analysis that predicts 
accurately relevant clinical outcomes in ADPKD patients, especially in young patients. 
Figure legend: 
Figure 1: Overview of the different kidney diseases, which were successfully investigated in 
the context of clinical urinary proteome analysis. The arrows pointed out in which area of the 
renal system the disease appears. Abbreviations: ADPKD - autosomal dominant polycystic 
kidney disease; DN – diabetic nephropathy; FIKD – Fabry induced kidney disease; FSGS - 
focal segmental glomerulosclerosis; IgAN – IgA nephropathy; LN – lupus nephrithis; MCD – 
minimal changed disease; MGN - membranous glomerulonephritis; PUV - posterior urethral 
valves; UPJO - ureteropelvic junction obstruction; vasculitis - ANCA-associated vasculitis. 
 
Figure 2: Schematic depiction of the reviewed studies evaluating the performance of the 
CKD273-classifier in diagnosis and prognosis of CKD according to disease stage. The bars 
shows the CKD stages of the in the study included patients. Figure adapted from Critselis et 
al. (26). 
 
Table 1: Summary of recent publications for the diagnosis and prognosis of kidney 
diseases based on CE-MS. In some studies sensitivity, specificity, or AUCs are not reported. 
*added value of proteome analysis with respect to the currently used parameters 
Kidney 
disease 
Number of 
peptides Performance Accuracy References 
CKD 
273 
Diagnosis 
Sensitivity: 86% 
Specificity: 100% 
AUC: 0.96 
(55) 
DN Diagnosis 
Sensitivity: 95% 
Specificity: 89% 
AUC: 0.96 
(56) 
DN Prognosis AUC: 0.92 (57) 
DN Prognosis --- (58) 
CKD Prognosis --- (18) 
DN Diagnosis AUC: 0.95 (59) 
CKD Prognosis --- (60) 
CKD Prognosis AUC: 0.83* (61) 
CKD Diagnosis (Prognosis) 
Sensitivity: 95% 
Specificity: 100% 
AUC: 0.98 
(AUC: 0.91*) 
(22) 
CKD Prognosis --- (29) 
MGN 311 Diagnosis AUC: 0.87 
(34) 
FSGS 287 Diagnosis AUC: 0.88 
MCD 291 Diagnosis AUC: 0.77 
DN/HN 619 Diagnosis AUC: 0.92 
IgAN 116 Diagnosis AUC: 0.82 
Vasculitis 509 Diagnosis AUC: 0.95 
LN 172 Diagnosis AUC: 0.82 
ADPKD 142 Diagnosis Sensitivity: 85% Specificity: 94% (37) 
ADPKD 20 Prognosis AUC: 0.83 (38) 
FIKD 64 Diagnosis 
Sensitivity: 88% 
Specificity: 98% 
AUC: 0.97 
(41) 
UPJO 51 
Prognosis 
Sensitivity: 100% 
Specificity: 85% 
AUC: 0.92 
(62) 
Prognosis 
(age<1) 
Sensitivity: 83% 
Specificity: 92% 
AUC: 0.88 
(63) 
VUR 9 Diagnosis Sensitivity: 88% Specificity: 79% (64) 
PUV 12 Prognosis Sensitivity: 88% Specificity: 95% (65) 
 
Table 1
Figure 1
Figure 2
